Mirae Asset Global Etfs Holdings Ltd. Bei Gene, Ltd. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $41.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 5,000 shares of BGNE stock, worth $952,550. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,000
Previous 4,921
1.61%
Holding current value
$952,550
Previous $702,000
59.83%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
250Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.01 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.23 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$986 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$948 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$706 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $19.8B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...